Renub Research has recently published a report titled “Netherlands Diabetes Market, Size, Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis” providing a comprehensive analysis of the industry that includes market share insights. In addition, the report comprises competitor and regional research and contemporary extension in the Netherland Diabetes Market. Netherland Diabetes Market has expected to reach US$ 3.36 Billion by 2028.The Netherlands has a well-developed healthcare system that plays a crucial role in addressing the challenges posed by diabetes. The diabetes industry in the Netherlands encompasses various aspects, including prevention, diagnosis, treatment, and management of diabetes. The prevalence of diabetes in the Netherlands has been increasing in recent years, primarily due to factors such as an aging population, sedentary lifestyles, unhealthy dietary habits, and obesity. This has led to a growing demand for diabetes-related products and services.
The Netherlands has taken significant steps to combat diabetes and promote better management of the disease. The healthcare system focuses on early detection and prevention through regular screenings and public health campaigns. Additionally, there is a strong emphasis on education and self-management programs to empower individuals with diabetes to effectively manage their condition. Diabetes market growth is also characterized by advancements in technology and innovative solutions. Companies are developing cutting-edge devices, such as insulin pumps, continuous glucose monitoring systems, and smart insulin pens, to enhance diabetes management and improve the quality of life for individuals with diabetes. Netherlands Diabetes Market to grow with a CAGR of 4.23% from 2022 to 2028. The growing elderly population in the Netherlands, combined with a rising obesity risk, is resulting in an increasing prevalence of Type-2 diabetes among the Dutch population.
Furthermore, collaboration between healthcare providers, research institutions, and pharmaceutical companies is driving advancements in diabetes research and treatment options. Clinical trials and studies are conducted to evaluate the effectiveness of new therapies and interventions, contributing to the development of evidence-based practices. Diabetes market size is focused on comprehensive care, patient empowerment, and innovation. With a strong healthcare infrastructure, proactive measures, and a commitment to research and development, the country is making significant strides in addressing the challenges posed by diabetes and improving the well-being of individuals living with the condition.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=netherlands-diabetes-market-p.php
Segments – Market based on Devices
1. Continuous Glucose Monitoring (CGM)
2. Self-Monitoring Blood Glucose (SMBG)
3. Insulin Pen
4. Insulin Pump
Netherlands is witnessing a rise in the prevalence of Type-2 diabetes, primarily due to its increasing aging population
The Netherlands is witnessing an upward trend in Type-2 diabetes prevalence due to its aging population. As the number of elderly individuals grows, the risk factors associated with diabetes, such as sedentary lifestyles and unhealthy dietary habits, become more prevalent. This demographic shift necessitates focused attention on diabetes prevention, early detection, and effective management strategies. The healthcare system in the Netherlands is actively working to address these challenges by implementing preventive measures, promoting healthy lifestyles, and providing comprehensive care for individuals affected by Type-2 diabetes. Continued efforts are essential to manage the increasing burden of diabetes market and improve the overall health outcomes of the aging population in the Netherlands.
Netherlands government has taken proactive steps in addressing the challenges posed by diabetes through various initiatives
The Netherlands government has implemented various initiatives to address the challenges posed by diabetes in the country. These initiatives aim to prevent, diagnose, and manage diabetes effectively. The government has invested in public health campaigns and education programs to raise awareness about diabetes risk factors and promote healthy lifestyle choices.
Additionally, there is a strong emphasis on early detection through regular screenings and promoting access to diabetes care services. The government also supports research and innovation in diabetes management, fostering collaborations between healthcare providers, researchers, and pharmaceutical companies. These government initiatives play a crucial role in improving diabetes outcomes and enhancing the overall well-being of individuals living with diabetes in the Netherlands.
Insulin pen segment has emerged as the dominant player, capturing the largest market share in the industry
The insulin pen segment has emerged as the dominant market player, capturing the highest market share. This can be attributed to several factors, including the convenience, ease of use, and accuracy provided by insulin pens for diabetes management. The compact and portable design of insulin pens makes them a preferred choice for individuals requiring regular insulin injections.
Furthermore, technological advancements in insulin pen devices, such as dose memory, adjustable dosing options, and enhanced needle safety, have further propelled their popularity. With the growing prevalence of diabetes and the increasing demand for self-administered insulin, the insulin pen segment is expected to continue its upward trajectory in capturing a significant diabetes market share.
The Netherlands Diabetes Sub-Segment Analysis
1. Continuous Glucose Monitoring (CGM) – Netherlands Diabetes Market breakup from four viewpoints
1. Glucose Sensor Market & Forecast
2. CGM Transmitter Market & Forecast
3. CGM User
4. CGM Reimbursement
2. SMBG – Netherlands Diabetes Market breakup from five viewpoints
1. Test Strips Market and Forecast
2. Lancet Market and Forecast
3. Meter Market and Forecast
4. Blood Glucose (SMBG) Users
5. Blood Glucose Devices Reimbursement
3. Insulin Pen Market – Netherlands Diabetes Market breakup from six viewpoints
1. Disposable Insulin Pen
2. Reusable Insulin Pen
3. Smart Insulin Pen
4. Insulin Pen Needle Market
5. Insulin Pen Users
6. Reimbursement Policies
4. Insulin Pump Market – Netherlands Diabetes Market breakup from four viewpoints
1. Insulin Pump Market
2. Insulin Pump Users
3. Insulin Pump Products
4. Reimbursement Policies
Prominent companies operating in the diabetes industry in the Netherlands include B. Braun Melsungen AG, Sanofi, Eli Lilly and Company, Becton Dickinson (BD), Novo Nordisk A/S, Ypsomed AG, Biocon, Medtronic, Insulet Corporation, Abbott Laboratories, Terumo Corporation, and Dexcom Inc. These companies contribute to the development and distribution of innovative diabetes products, technologies, and services to support effective diabetes management and improve the quality of life for individuals living with diabetes in the Netherlands.
All the 13 Companies Studied in the Report have been Studied from 3 Points
• Company Overview
• Recent Developments
• Financial Insight
1. B. Braun Melsungen AG
2. Eli Lilly and Company
3. Terumo Corporation
4. Becton, Dickinson (BD)
5. Novo Nardisk,
6. Ypsomed AG
8. Insulet Corporation
9. Abbott Laboratories
10. DarioHealth Crop
11. Dexcom, Inc
12. Roche Diagnostic
13. Tandem Diabetes Care
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)